Ibex Medical Analytics vs Vesta
Ibex Prostate Detect was cleared on January 24, 2025 as 510(k) K241232, and Ibex describes its solutions as helping pathologists detect and grade cancer. It says its breast and gastric tools are research use in the US, and it lists an open API for scanners, image management and LIS. It sells to laboratories and health systems on enterprise contracts and raised a $55M Series C in September 2023, led by 83North.
Vesta answers a different question. It scores routine H&E slides from patients with non-muscle-invasive bladder cancer to flag likely BCG non-response, and the vendor says biomarker-present patients have twice the risk of non-response. The Vesta papers on PubMed carry a Valar affiliation.
A laboratory or health system buys Ibex, and a treating urologist orders Vesta, so neither purchase stands in for the other.
Pathology · Reviewed November 2, 2026
Ibex Medical Analytics
by Ibex
AI pathology software for prostate, breast and gastric cancer. One US FDA 510(k) clearance, for prostate.
Vesta
by Valar Labs
Lab test run in a CLIA lab: AI on routine bladder cancer slides predicts BCG response, ordered by urologists.
When to pick each one
Ibex Medical Analytics
- Prostate Detect cleared, K241232, January 2025
- Open API to scanners, image management, LIS
Vesta
- BCGPredict targets BCG response in bladder cancer
- Risk Stratify scores recurrence and progression
Score
Each row shows points earned of points available under the published rubric.
Ibex Medical Analytics
33of 100
Vesta
16of 100
| Dimension | Ibex Medical Analytics | Vesta | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 0 / 18 | +18 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 8.4 / 21 | -8.4 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 3 / 12 | +5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Ibex Medical Analytics
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Sold to laboratories and health systems on enterprise contracts. |
Vesta
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Ibex Medical Analytics
FDA decisions
K241232 (opens in new tab)510(k)2025-01-24
Galen Second Read (Ibex Prostate Detect)
Vesta
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names Vesta.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Ibex Medical Analytics | Vesta |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | IL | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.